iBio Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting to be Held on December 9
October 26 2021 - 8:35AM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of
next-generation biopharmaceuticals and pioneer of the sustainable,
plant-based
FastPharming Manufacturing System®,
today urged its stockholders to vote “FOR” all proposals put forth
in the proxy statement prior to the Company’s December 9, 2021
Annual Meeting of Stockholders.
Stockholders are advised that, because two of
the voting proposals involve a proposed amendment to the Company’s
Articles of Incorporation, the holders of a majority of outstanding
common shares must approve such proposals.
Stockholders holding common stock at the close
of business on Friday, October 15, 2021, are entitled to vote at
the meeting, even if they have subsequently sold their shares.
YOUR VOTE IS IMPORTANT –
NO MATTER HOW MANY OR HOW FEW SHARES YOU OWN
“Ahead of our 2021 Annual Meeting, we are
encouraging our shareholders to actively participate in the proxy
voting process. Their input is vital for the continued strategic
growth and development of the Company,” said Tom Isett, Chairman
& CEO of iBio. “Of course, our Board of Directors is elected to
represent our shareholders, and the Board’s voting recommendations
reflect its continued confidence in the long-term growth and
financial performance of our Company. While we encourage
shareholders to support the Board’s recommendations, we want to
hear everyone’s voice. Thus, we urge everyone eligible to
participate in the process and vote.”
“Since the filing of our preliminary proxy
materials, we have been pleased to see a high level of shareholder
engagement. To help facilitate continued dialogue, we have created
a new Q&A page in the Investors section of our website based
upon inquiries to date. We plan to update that page, if needed,
leading up to the meeting,” concluded Mr. Isett.
To vote their shares, stockholders should locate
the control number on their proxy card or voting instruction form
and follow the voting instructions. If they do not have a proxy
card or voting instruction form, they can call Okapi Partners at
1-844-203-3605 (U.S. and Canada) or +1-212-297-0720 (from other
locations) from 9:00 a.m. ET to 8:00 p.m. ET Mondays – Fridays for
assistance.
Important Information
This communication may be deemed to be
solicitation material in connection with the proposals to be
considered at iBio’s 2021 Annual Meeting of Stockholders. In
connection with the proposals, the Company filed a definitive proxy
statement on Schedule 14A with the U.S. Securities and Exchange
Commission (the “SEC”) on October 26, 2021. Shareholders are urged
to read the definitive proxy statement and all other relevant
documents filed with the SEC because they contain important
information about the proposals. An electronic copy of the
definitive proxy statement is available on the Company’s website at
www.ibioinc.com under "SEC Filings" in the Investors section, and
on the Company’s EDGAR profile at www.sec.gov.
About iBio, Inc.
iBio is a developer of next-generation
biopharmaceuticals and a pioneer in sustainable, plant-based
biologics manufacturing.
Its FastPharming System® combines
vertical farming, automated hydroponics, and novel glycosylation
technologies to rapidly deliver high-quality monoclonal antibodies,
antigens, and other proteins. iBio is developing proprietary
biopharmaceuticals for the treatment of cancers, as well as
fibrotic and infectious diseases. The Company’s subsidiary, iBio
CDMO LLC, provides FastPharming Contract
Development and Manufacturing Services along
with Glycaneering Development
Services™ for advanced recombinant protein design. For more
information, visit www.ibioinc.com.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release
constitute "forward-looking statements" within the meaning of the
federal securities laws. Words such as "may," "might," "will,"
"should," "believe," "expect," "anticipate," "estimate,"
"continue," "predict," "forecast," "project," "plan," "intend" or
similar expressions, or statements regarding intent, belief, or
current expectations, are forward-looking statements. These
forward-looking statements are based upon current estimates and
assumptions and include statements regarding the anticipated
effects of stockholder approval of matters to be voted on at iBio’s
2021 annual meeting of stockholders (the "Annual Meeting"). While
the Company believes these forward-looking statements are
reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are subject to various risks and uncertainties, many of
which are difficult to predict that could cause actual results to
differ materially from current expectations and assumptions from
those set forth or implied by any forward-looking statements.
Important factors that could cause actual results to differ
materially from current expectations include, among others, the
Company’s ability to successfully hold its 2021 Annual Meeting, its
ability to implement its development plans, its ability to obtain
regulatory approvals for commercialization of its product
candidates, including its COVID-19 vaccines, or to comply with
ongoing regulatory requirements, regulatory limitations relating to
its ability to promote or commercialize its product candidates for
specific indications, acceptance of its product candidates in the
marketplace and the successful development, marketing or sale of
products; its ability to maintain its license agreements; the
continued maintenance and growth of its patent estate, its ability
to establish and maintain collaborations, its ability to obtain or
maintain the capital or grants necessary to fund its research and
development activities and whether the Company will incur
unforeseen expenses or liabilities or other market factors,
successful compliance with governmental regulations applicable to
its manufacturing facilities, competition, its ability to retain
its key employees or maintain its NYSE American listing, its
ability to increase its authorized shares, and the other factors
discussed in the Company’s filings with the SEC including the
Company’s most recent Annual Report on Form 10-K and the Company’s
subsequent filings with the SEC on Forms 10-Q and 8-K. The
information in this release is provided only as of the date of this
release, and we undertake no obligation to update any
forward-looking statements contained in this release on account of
new information, future events, or otherwise, except as required by
law.
Contact:Stephen KilmeriBio, Inc.Investor
Relations(646) 274-3580skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024